The Case CCC Athymic Animal &Xenograft Core Facility includes two sites, one at CWRU and one at CCF. The Core is directed by Daniel Lindner and co-directed by Lili Liu. Case CCC members from 7 of the 8 research programs utilize the Core for their studies. In particular, the Cancer Cell Signaling, GU Malignancies, Hematopoietic Disorders, and Developmental Therapeutics Programs utilize the Core. The Core provides a facility for breeding and housing of athymic nude mice (NCRnu/nu), NOD-SCID mice, and other immunodeficient animals. The Core also provides pathogen-free facilities for experimentation using immunodeficient animal hosts and xenografts of human cell lines, human tumors, and normal human cells, in particular hematopoietic cells. The Core helps investigators design and perform experiments, tumor measurements, draw blood samples, and monitoring functions. Core staff maintain and monitor animals housed in the facility, and provide users with many services that facilitate research projects including transportation from one site to another, transportation to the animal imaging and radiation facilities, health reports, animal handling, and animal handling training. For individual investigator research, the Core teaches experimental techniques and performs experimental procedures. Investigators use mice in the facility for studies of human tumor xenografts to test anticancer drug effects on syngeneic murine tumor implants, to determine species-specific effect of cytokines and evaluate cytotoxic T cell (CTL) response to tumor associated antigens;to test oncogenicity of specific tumor genes on human tumor xenografts;and to perform small animal imaging to detect cancer size and location, as well as anticancer drug distribution and pharmacokinefic study in vivo. The Core has provided key support for studies investigating combination treatment of the protein tyrosine phosphatase (PTPase) inhibitors with agents that sensitize inhibitor resistant tumors in mouse models. Mouse tumor studies performed by the Core were pivotal to delineate the role and mechanism of action of oncogenic PTPases in malignant diseases. In addition. Xenograft studies were critical to study the growth inhibitory effects of apigenin;to determine whether pharmacologic intervention with apigenin has a direct growth inhibitory effect on human prostate tumors implanted in athymic nude mice;and to examine cell cycle regulatory molecules as precise molecular targets of apigenin action.

Public Health Relevance

The Case Comprehensive Cancer Center is Northeast Ohio's only NCI designated comprehensive cancer center providing bench-to-bedside medical research involving partnerships between basic, clinical and population scientists to speed translation of laboratory discoveries into new prevention/intervention and cancer treatments.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA043703-24
Application #
8765394
Study Section
Subcommittee B - Comprehensiveness (NCI)
Project Start
Project End
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
24
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Case Western Reserve University
Department
Type
DUNS #
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Patel, Rutulkumar; Qing, Yulan; Kennedy, Lucy et al. (2018) MMR Deficiency Does Not Sensitize or Compromise the Function of Hematopoietic Stem Cells to Low and High LET Radiation. Stem Cells Transl Med 7:513-520
Desai, Amar; Zhang, Yongyou; Park, Youngsoo et al. (2018) A second-generation 15-PGDH inhibitor promotes bone marrow transplant recovery independently of age, transplant dose and granulocyte colony-stimulating factor support. Haematologica 103:1054-1064
Cummings III, Kenneth C; Zimmerman, Nicole M; Maheshwari, Kamal et al. (2018) Epidural compared with non-epidural analgesia and cardiopulmonary complications after colectomy: A retrospective cohort study of 20,880 patients using a national quality database. J Clin Anesth 47:12-18
Thiagarajan, Praveena S; Sinyuk, Maksim; Turaga, Soumya M et al. (2018) Cx26 drives self-renewal in triple-negative breast cancer via interaction with NANOG and focal adhesion kinase. Nat Commun 9:578
Qiu, Zhaojun; Oleinick, Nancy L; Zhang, Junran (2018) ATR/CHK1 inhibitors and cancer therapy. Radiother Oncol 126:450-464
Elitt, Matthew S; Shick, H Elizabeth; Madhavan, Mayur et al. (2018) Chemical Screening Identifies Enhancers of Mutant Oligodendrocyte Survival and Unmasks a Distinct Pathological Phase in Pelizaeus-Merzbacher Disease. Stem Cell Reports 11:711-726
He, Tian; McColl, Karen; Sakre, Nneha et al. (2018) Post-transcriptional regulation of PIAS3 expression by miR-18a in malignant mesothelioma. Mol Oncol 12:2124-2135
Roche, Kathryn L; Nukui, Masatoshi; Krishna, Benjamin A et al. (2018) Selective 4-Thiouracil Labeling of RNA Transcripts within Latently Infected Cells after Infection with Human Cytomegalovirus Expressing Functional Uracil Phosphoribosyltransferase. J Virol 92:
Bedell, Hillary W; Hermann, John K; Ravikumar, Madhumitha et al. (2018) Targeting CD14 on blood derived cells improves intracortical microelectrode performance. Biomaterials 163:163-173
Nagaraj, A B; Wang, Q Q; Joseph, P et al. (2018) Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment. Oncogene 37:403-414

Showing the most recent 10 out of 1227 publications